Emergent Continues to Expand Role in Support of Development and Manufacturing of COVID-19 Vaccines

Emergent BioSolutions recently announced that it has been issued a task order under an existing contract with the Biomedical...

READ MORE

Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing

  • Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid...
READ MORE

May 4th Webinar: Rapid Readiness for Pandemic Response

Watch our latest webinar on the topic of how drug developers can maximize capacity, capabilities and expertise for pandemic...

READ MORE

Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19

GAITHERSBURG, Md., April 23, 2020 (GLOBE NEWSWIRE)

Emergent BioSolutions Inc. (NYSE:EBS) today announced an agreement whereby...

READ MORE

Webinar: Finding Solutions for public health threats: COVID-19

What are innovators doing to speed up the path to treating and preventing COVID-19?

The novel coronavirus has quickly taken...

READ MORE

Novavax + Emergent: In the news

Original news coverage of Novavax's agreement with Emergent BioSolutions to manufacture and develop an experimental oral vaccine...

READ MORE
WANT MORE INFORMATION?

Learn more about Emergent CDMO’s work and the many milestones we’ve reached in our news release archive below.  If you’re a media representative, please feel free to contact us at cdmo@ebsi.com.

Interested in learning more about Emergent BioSolutions, Inc.? Please visit emergentbiosolutions.com.

WANT MORE INFORMATION?

Learn more about Emergent CDMO’s work and the many milestones we’ve reached in our news release archive below.  If you’re a media representative, please feel free to contact us at mediarelations@ebsi.com.

Interested in learning more about Emergent BioSolutions, Inc.? Please visit emergentbiosolutions.com.